Treatment Of Chronic Obstructive Pulmonary Disease With The Treatment Of Tiotropium/Olodaterol:A Meta-analysis

Objective:To evaluate the clinical efficacy and safety of tiotropium / olodaterol in the treatment of COPD by using Meta analysis method.Methods:We searched PubMed, the Cochrane Library, Ovid database, CNKI,Wanfang database etc., collect randomized controlled trials on treatment for COPD with TIO/OLO 5?g/5?g, and references of included retrospective. Data extraction and quality assessment of the data after the inclusion and exclusion criteria were established in advance. According to the results of literature heterogeneity test, we use random effects model or fixed effect model for meta analysis by Stata 12.0.Results:According to the inclusion and exclusion criteria, there are 8 trials including10 articles, a total of 8387 samples were included in the study for Meta-analysis,evaluation of the efficacy and safety of TIO/OLO5 ? g/5 ? g in the treatment of COPD.The results showed that application TIO/OLO combination therapy compared to single drug or placebo in the treatment of chronic obstructive pulmonary disease(COPD) can effectively improve the patient's pulmonary function, improve symptoms,improve the quality of life of patients, but does not increase the incidence of adverse reactions. Pulmonary function: through the analysis of FVC, FEV1, compared with the single drug group, FEV1:SMD=6.719, 95%CI(4.807, 8.630),p=0.000;FVC:SMD=4.947, 95%CI(3.280-6.614), p=0.000. Compared to the placebo group, FEV1:SMD=19.306, 95%CI(12.098-26.514), p=0.000. The results showed that the combined treatment could improve the lung function of the patients. St George's Respiratory Questionnaire(SGRQ) score, compared to single drug group,SMD =-3.374, 95% CI(-4.138,-2.609), P = 0.000, indicating that combination therapy can improve the quality of life of the patients. Transitional dyspnoea Index(TDI) score, compared to single drug group, SMD = 3.603, 95%CI(3.036-4.170),p=0.000, showed that the combination treatment can improve the patient's symptoms.Adverse reactions: the combination therapy group compared to single drug or a placebo. The OR value of 95% CI are null and void value 1 intersect, P values were greater than 0.05, indicating that the treatment in the two groups had no significant difference between combination therapy did not increase the drug adverse reaction incidence rate.Conclusion: Tiotropium bromide / olodaterol in the Treatment with COPD can improve lung function, relieve symptoms and improve the quality of life of patients, and not increase the incidence rate of the drug adverse reaction.